Liver transplant recipients show significantly poorer lung function than general population

A Danish research team has documented something that appears to have been largely overlooked in transplant medicine: people who receive a new liver develop lung problems at rates substantially higher than the general population. The finding comes from a nationwide study comparing 512 adult liver transplant recipients with 2,010 matched adults drawn from the broader population, all of whom underwent spirometry testing to measure how well their lungs work.

The numbers tell a clear story. Among liver transplant recipients, airflow limitation—a hallmark of obstructive lung disease—showed up in just over one in ten patients. In the control group, it appeared in roughly one in fourteen. That 50 percent difference held up under statistical scrutiny. A pattern called PRISm, which indicates preserved lung volume alongside impaired airflow, was even more striking: it affected nearly a quarter of transplant recipients but only about one in eight controls. When researchers asked patients directly about breathlessness, transplant recipients reported it more frequently and more severely than their matched counterparts.

What makes these findings significant is that they persisted even after the researchers accounted for the factors you might expect to explain lung problems—age, sex, smoking history, educational background. After adjusting for all of that, liver transplant recipients still carried more than double the odds of airflow limitation. For the PRISm pattern, the odds were nearly triple. The actual lung volumes told the same story: transplant recipients showed forced expiratory volume measurements that were 363 milliliters lower than controls, and forced vital capacity that was 549 milliliters lower. These are not marginal differences. They represent clinically meaningful reductions in how much air people can move through their lungs.

Among the transplant recipients themselves, those with a history of pulmonary infection faced even steeper risk. A previous lung infection more than doubled the odds of developing airflow limitation in this population. The researchers cannot yet say definitively why liver transplant recipients develop these chronic lung problems. The consistency of the findings across multiple measures of lung function—spirometry readings, airflow patterns, and what patients themselves report about their breathing—suggests the effect is real and substantial, but the mechanism remains unclear. Immunosuppression, the medications transplant recipients must take for life to prevent rejection, may play a role. Infection history clearly matters. Other factors may be at work as well.

What the study does establish is that chronic lung disease after liver transplantation appears to be far more common than current clinical practice typically recognizes. Transplant recipients are monitored closely for rejection, infection, and organ function, but pulmonary complications have largely been framed as acute problems—infections that develop in the weeks or months after surgery. This research suggests that clinicians should be watching for something different: a slower, persistent decline in lung function that develops over time and affects a substantial portion of the transplant population. The practical implication is straightforward. When a liver transplant recipient reports breathlessness or shows signs of reduced lung function, that warrants investigation. Identifying these patients early may open the door to interventions that could slow decline or improve quality of life—a consideration that matters enormously for people who have already undergone major surgery and committed to a lifetime of medication.